Argenx advances clinical development of efgartigimod sc in idiopathic inflammatory myopathies

Phase 2 data establish proof-of-concept of efgartigimod sc in myositis enrollment to continue in phase 3 across all three subtypes (imnm, asys, dm) under evaluation in alkivia potential for efgartigimod sc to be first targeted approach for myositis patients who have limited treatment options november 20, 2024, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous (sc) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing phase 2/3 alkivia study in adults with idiopathic inflammatory myopathies (iim or myositis), following analysis of topline data from the phase 2 portion of the study. alkivia will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy (imnm), anti-synthetase syndrome (asys), and dermatomyositis (dm).
ARGX Ratings Summary
ARGX Quant Ranking